lagis

DOCKET NO.: RTS-0341

Date of Deposit: 11/29/2001



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Mark J. Graham and Kenneth Dobie

For:

Antisense Modulation of CD81 Expression

BOX SEQUENCE

Assistant Commissioner for Patents

Washington DC 20231

DATE OF DEPOSIT: 1129 2001
I HEREBY CERTIFY THAT THIS PAPER DEPOSITED WITH THE UNITED STATES A SERVICE AS FIRST CLASS MAIL, POSTAC PREPAID ON THE DATE INDICATED ABOVE IS ADDRESSED TO THE ASSISTANT COMMISSIONER FOR PATENTS, WASHING REGISTRATION NO

PATENT APPLICATION TRANSMITTAL LETTER

Transmitted herewith for filing, please find the following:

To The Specification of the above-referenced patent application;

- $f{^{\prime}}$ An Assignment of the invention to $f{Isis}$ $f{Pharmaceuticals}$ $f{Inc.}$ with recordation cover sheet (PTO Form PTO-1595) and \$40.00 cover fee;
- · Statement to Support Filing and Submission of DNA/Amino Acid Sequences in Accordance with 37 CFR § § 1.821 through 1.825;
- Sequence listing in computer readable form in accordance with 37 C.F.R. § 1.821(e);
- An Information Disclosure Statement with references; and
- Applicant claims small entity status pursuant to 37 CFR § 1.27; and
- · Statement of attempt to deposit correspondence with the USPS via Express

The filing fee has been calculated as shown below:

For:	No. Filed	No. Extra	Rate	Fee
BASE FEE				\$370.00
Total Claims	20 - 20 =	0	X \$9=	\$0
Indep. Claims	2 - 3 =	0	x\$40=	\$0
TOTAL				\$ 370.00

The Commissioner is hereby authorized to charge the following fees to Deposit Account No. 500252:

- the amount of \$410.00 for the above listed fees;
- · payment of the following fees associated with this communication or credit any overpayment;
- any additional filing fees required under 37 CFR 1.16 including fees for presentation of extra claims; and
- · any additional patent application processing fees under 37 CFR 1.17 and under 37 CFR 1.20 (d).

Triplicate copies of this transmittal are enclosed,

Date: November 29, 2001

Donna T. Ward

Registration No. 48,271 Isis Pharmaceuticals, Inc.

Please address all correspondence to:

Jane Massey Licata or Kathleen A. Tyrrell Licata & Tyrrell, P.C. 66 East Main Street Marlton NJ 08053

(856) 810-1515

DOCKET NO.: RTS-0341 DE 18 2001 Date of Deposit: 1129/2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s): William Gaarde and Andrew T. Watt

Serial No.: not yet assigned Filing Date: herewith

Title: Antisense Modulation of Connective Tissue Growth Factor Expression

Statement of attempt to deposit correspondence with the USPS via Express Mail.

Date of attempt to deposit via Express Mail: 11290 I hereby certify that I attempted to deposit this correspondence with the USPS via Express Mail on the above date. The USPS refused to accept this correspondence on said date.

Date: Nevember 29, 2001

Typed Name: Pamela Grooms

I hereby certify that all statements made herein are true.

Dohna T. Ward

Registration No.: 48,271

Please address all correspondence to:

Jane Massey Licata or Kathleen A. Tyrrell Licata & Tyrrell, P.C. 66 East Main Street Marlton NJ 08053 (856) 810-1515



DOCKET NO.:RTS-0341

Date of Deposit: 11/79/7001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s): Mark J. Graham and Kenneth Dobie

Serial No.: not yet assigned Filing Date: herewith

Title: Antisense Modulation of CD81 Expression

BOX SEQUENCE Assistant Commissioner for Patents Washington, D.C., 20231

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 C.F.R. §§ 1.821 THROUGH 1.825

I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same.

Date: Movember 29,2001

Respectfully submitted,

Registration No. 48,271
Isis Pharmaceuticals, Inc.

Please address all correspondence to:

Licata & Tyrrell, P.C. 66 East Main Street Marlton NJ 08053 (856) 810-1515